Publications, Pharmaceutical

Why it is time to think differently about Nasal delivery of Biologics

COVID-19 has reinvigorated interest in the advantages of nasal delivery for a pharmaceutical industry already embracing a shift towards biologics.

This article considers the challenges and potential benefits of combining the two. The nasal delivery of biologics offers considerable potential for both local and systemic action and for direct access to the brain and CNS to address currently unmet therapeutic need. The unique features of biologics are discussed with reference to the associated difficulties of nasal delivery and the benefits of partnership with experts such as Aptar Pharma is highlighted. Work on the development of vaccines and prophylactics for COVID-19 illustrates what is achievable.

Download Publication
Author(s): Gemma Budd Irene Rossi
4 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

5 Oct 2020

Reusable systems and recyclable packaging aid pharma sustainability

Publications, Pharmaceutical, Sustainability, Innovation & Insights, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
15 Jun 2020

Accelerating the development of COVID vaccines and therapeutics

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
1 Jun 2020

Aptar Pharma expert Q&A on digital health and connected drug delivery

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
26 May 2020

Aptar Pharma discusses Article 117 of the Medical Device Regulations

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
1 … 19 20 21 22 23 … 25

How Can We Help?

Back To Top